相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images
Pegah Khosravi et al.
EBIOMEDICINE (2018)
Next generation predictive biomarkers for immune checkpoint inhibition
Yulian Khagi et al.
CANCER AND METASTASIS REVIEWS (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J. Kaunitz et al.
LABORATORY INVESTIGATION (2017)
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
Hans Brunnstrom et al.
MODERN PATHOLOGY (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors
Aino Paasinen-Sohns et al.
NEOPLASIA (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Evaluating harmonization of PD-L1 assays using image analysis
Nathan T. Martin et al.
CANCER RESEARCH (2017)
Evaluating benefits of PD-L1 image analysis for the clinical setting
Staci Kearney et al.
CANCER RESEARCH (2017)
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore et al.
CLINICAL CANCER RESEARCH (2016)
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
Jacquelyn Smith et al.
DIAGNOSTIC PATHOLOGY (2016)
Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome
Kanika Garg et al.
HUMAN PATHOLOGY (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Enric Domingo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
D. Massi et al.
ANNALS OF ONCOLOGY (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak et al.
ORAL ONCOLOGY (2015)
Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
Daniel H. Hovelson et al.
NEOPLASIA (2015)
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
James Larkin et al.
JAMA ONCOLOGY (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
Nemanja Rodic et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma
Jules Gadiot et al.
CANCER (2011)
Defining the critical hurdles in cancer immunotherapy
Bernard A. Fox et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
分享论文
